Tier 2 — strong

Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults

Conze D, Brenner C, Kruger CL
Scientific reports 2019 9; 1; 9772

Bibliography

PubMed
PMID 31278280
PubMed Central
PMC6611812
Funding
ChromaDex funded the trial.
Competing interests
Disclosures include ChromaDex employment, advisory work and licensed intellectual property.

Study snapshot

DesignRandomized placebo-controlled human trial
ModelHuman participants
Sample140 adults; 35 randomized per arm
InterventionNR chloride 100, 300 or 1000 mg/day versus placebo
Duration8 weeks
EndpointsBlood NAD+ metabolites; adverse events; safety laboratory measures

What the study showed, in plain terms

NR produced dose-dependent whole-blood NAD+ increases without a significant difference in reported adverse events versus placebo.

Key findings

The reported NAD+ increases at two weeks were 22%, 51% and 142% across increasing doses.

What this study can and cannot tell us

Short study in otherwise healthy overweight adults; the title’s long-term wording should not be read as multi-year follow-up.

Citation network

Articles citing this research paper

10 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified